Asosiy kontentga oʻtish
Sharh maqola

Noncoding RNA Regulation of Ferroptotic Vulnerability in Oxaliplatin-Resistant Colorectal Cancer: A Critical Narrative Review Beyond the Canonical ceRNA Model

Safwan AladwanFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, JordanBahjat AlhassoGopalakrishnan PadmapriyaDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, IndiaSamir SahuInstitute of Medical Sciences and Sum HospitalShrey Kumar SrivastavDepartment of General Medicine, Sharda University, Knowledge Park III, Greater Noida, IndiaAnju RaniDepartment of Nutrition and Dietetics, Chandigarh University, Mohali, Punjab, IndiaTulkin BuzrukovDepartment of Medicine, Termez University of Economics and Service, Termez, UzbekistanJasur RizaevDepartment of Public Health and Healthcare management, Rector, Samarkand State Medical University, Samarkand, Uzbekistan
2026en
ABI

Annotatsiya

Oxaliplatin (OXA) resistance remains a major limitation in colorectal cancer (CRC), and ferroptosis is being investigated as a potential therapeutic vulnerability. Non-coding RNAs (ncRNAs) may influence ferroptotic sensitivity through redox metabolism, iron homeostasis, lipid remodeling, and tumor–microenvironment interactions. However, many proposed ncRNA-mediated mechanisms, particularly competing endogenous RNA (ceRNA) models, remain insufficiently validated. This critical narrative review synthesizes selected experimental reports and is not a systematic or exhaustive review. The reports discussed were organized into four evidence categories: direct ncRNA–OXA–ferroptosis investigations; OXA–ferroptosis studies without ncRNA perturbation; ncRNA–ferroptosis studies without OXA testing; and ncRNA–OXA studies lacking ferroptosis-specific validation. These categories describe the directness of evidence, not formal study-quality scores. Among the selected reports, only two linked ncRNA regulation with both OXA response and ferroptosis: SNHG4 via PTEN RNA stability and lncRNA-HMG via p53–MDM2 and SLC7A11/VKORC1L1 regulation. Neither demonstrated a complete PI3K/AKT–NRF2–SLC7A11/GPX4 pathway or endogenous ceRNA competition. Other studies implicated NRF2/GPX4, SLC7A11, ACSL4-dependent lipid remodeling, iron regulation, FSP1, DHODH, mitochondrial metabolism, microbiota, and extracellular vesicles. Given heterogeneity in models, treatments, endpoints, and validation, links across studies remain hypothesis-generating. Overall, the evidence supports a context-dependent ferroptotic-threshold framework rather than a universal ncRNA-driven pathway. Future work should use endogenous ncRNA perturbation, quantitative ceRNA validation, ferroptosis-specific rescue, and patient-derived models.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar